Arvinas ARVN 深 沪
已收盘 12-12 16:00:00 美东时间
12.58
+0.010
+0.08%
华盛通- 最 高12.90
- 今 开12.64
- 成交量 79.52万股
- 最 低 12.47
- 昨 收 12.57
- 总市值 9.24亿
- 52周最高 21.00
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 5.90
- 委 比 -59.41%
- 总股本 7341.76万
- 历史最高 108.465
- 量 比 0.71
- 振 幅 3.42%
- 历史最低 5.90
- 每 手 1
- 风险率 4.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arvinas Reveals Promising Preclinical Data for ARV-393
The latest announcement is out from Arvinas Holding Company ( ($ARVN) ). On Dec...
12-08 19:55
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Arvinas announced preclinical data showing ARV-393, a PROTAC BCL6 degrader, combined with glofitamab, a CD20×CD3 bispecific antibody, significantly enhanced tumor growth inhibition (TGI) in a humanized high-grade B-cell lymphoma (HGBCL) model. The combination achieved 81% and 91% TGI with concomitant and sequential dosing, respectively, compared to 38% and 36% for single agents. These findings support the potential for a chemotherapy-free combina...
12-06 13:05
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Arvinas, Inc. announced that its Chief Medical Officer, Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer, Andrew Saik, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4 at 11:00 a.m. ET in New York. A live audio webcast will be available on the company’s website. Arvinas specializes in developing targeted protein degradation therapies using its PROTAC platform to treat debilitating di...
11-26 12:00
美股牛股 | 嘉楠科技飙升20%，Q3挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作
嘉楠科技飙升20%，Q3营收破1.5亿美元，挖矿收入激增241%；Diginex涨超19%，公司与EVIDENT达成战略合作>>
11-19 16:54
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Olema Pharmaceuticals (NASDAQ:OLMA) stock increased by 137.7% to $20.2...
11-19 01:06
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
11-18 02:07
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Barclays Maintains Overweight on Arvinas, Raises Price Target to $16
Barclays analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target from $15 to $16.
11-06 22:27
Arvinas Q3 EPS $(0.48) Beats $(0.81) Estimate, Sales $41.900M Beat $23.600M Estimate
Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.81) by 40.96 percent. This is a 29.41 percent increase over losses of $(0.68) per share from the same
11-05 20:06
